Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16316636 | 0.93 | PGR (0.33) | PGR | |
| SCHEMBL21362063 | 0.76 | TRPM5 (0.31) | — | |
| SCHEMBL22304436 | 0.70 | — | — | |
| SCHEMBL12228897 | 0.70 | PGR (0.41) | PGR | |
| SCHEMBL30788048 | 0.70 | PGR (0.41) | PGR | |
| SCHEMBL12228849 | 0.70 | TDO2 (0.35) | — | |
| SCHEMBL17278422 | 0.68 | CHRNB2 (0.38) | PGR | |
| SCHEMBL25995484 | 0.68 | L3MBTL1 (0.38) | PGR | |
| SCHEMBL18421462 | 0.68 | PGR (0.46) | PGR | |
| SCHEMBL23625928 | 0.67 | ULK1 (0.35) | PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11724987-B2 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-11583529-B2 | Treatment of inflammatory disorders | ALDEYRA THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230041335-A1 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | ALDEYRA THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20220133697-A1 | INJECTABLE FORMULATIONS | ALDEYRA THERAPEUTICS, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20210353628-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2021-11-18 | — | — | US | disclosed |
| US-11040039-B2 | Treatment of inflammatory disorders | ALDEYRA THERAPEUTICS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-9364471-B2 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9265759-B2 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150209333-A1 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2015-07-30 | — | — | US | disclosed |
| US-20150209345-A1 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2015-07-30 | — | — | US | disclosed |
| US-8940764-B2 | Compositions and methods of treating retinal disease | ALDEXA THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940721-B2 | Compositions and methods of treating retinal disease | ALDEXA THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20110263645-A1 | Compositions and Methods of Treating Retinal Disease | NEURON SYSTEMS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7973025-B2 | Compositions and methods of treating retinal disease | NEURON SYSTEMS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090182009-A1 | Compositions and methods of treating retinal disease | NEURON SYSTEMS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20070135481-A1 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041335-A1 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | ALDH1A2, PLA2G2E, CLN6 | PGR 3677/4885 |
| US-20150209345-A1 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | ALDH1A2, CLN6, PLA2G2E | PGR 3563/4885 |
| US-20090182009-A1 | Compositions and methods of treating retinal disease | ALDH1A2, PLA2G2E, CLN6 | PGR 3677/4885 |
| US-11040039-B2 | Treatment of inflammatory disorders | TNF, NFKBIA, LTB4R2 | PGR 1434/4885 |
| US-11724987-B2 | Compositions and methods of treating retinal disease | ALDH1A2, PLA2G2E, CLN6 | PGR 3677/4885 |
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | TNF, NFKBIA, LTB4R2 | PGR 1434/4885 |
| US-11583529-B2 | Treatment of inflammatory disorders | TNF, NFKBIA, LTB4R2 | PGR 1434/4885 |
| US-20220133697-A1 | INJECTABLE FORMULATIONS | ALDH2, CLN6, ALDH1A1 | PGR 1924/4885 |
| US-20150209333-A1 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | ALDH1A2, PLA2G2E, CLN6 | PGR 3677/4885 |
| US-20210353628-A1 | TREATMENT OF INFLAMMATORY DISORDERS | TNF, NFKBIA, LTB4R2 | PGR 1434/4885 |
| US-20070135481-A1 | Compositions and methods of treating retinal disease | ALDH1A2, PLA2G2E, CLN6 | PGR 3677/4885 |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | TNF, NFKBIA, LTB4R2 | PGR 1434/4885 |
| US-20110263645-A1 | Compositions and Methods of Treating Retinal Disease | ALDH1A2, CLN6, PLA2G2E | PGR 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.